BioSpace News Archive

Salubris Biotherapeutics, Inc. announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.

Evotec SE announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb, originally signed in 2016.

Backed by international investors, Atrandi Biosciences is establishing a direct team to support customers in the U.S. and advancing the global commercialization of its breakthrough microfluidic and single-cell analysis technologies.

BioNTech SE announced that it has entered into a new share repurchase program, pursuant to which the Company may purchase American Depositary Shares, each representing one ordinary share, of the Company in the amount of up to $0.5 billion during the remainder of 2023.

Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status effective April 1, 2023, for the DCISionRT® test.

Tigermed Consulting Co., Ltd. announced its annual results for the year ended December 31, 2022 (the “Reporting Period”).

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis.

GenesisCare, one of the leading integrated cancer care providers in the United States, Australia, Spain, and the United Kingdom, will launch ViewRay’s advanced MRIdian MRI-guided radiation therapy system at the Lee Health Regional Cancer Center on Monday, March 27, at its Fort Myers, FL location.

ANANDA Scientific Inc. today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).

Switch Therapeutics today announced the appointments of Craig Blanchette, Ph.D., as Senior Vice President, Research and Michael Wolfe as Senior Vice President, Finance and Operations, effective immediately.